Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki- ras mutation

Molecular Carcinogenesis

Volumn 20, Issue 2, 1997, Pages 251-258

  Aoki, Kazunori ^a   Yoshida, Teruhiko ^a   Matsumoto, Nobuyuki ^a   Lde, Hisamitsu ^a   Sugimura, Takashi ^a   Terada, Masaaki ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Antisense; Cell growth; Ki ras; p21; Pancreatic cancer

Indexed keywords

PROTEIN P21;

ARTICLE; CANCER THERAPY; CELL TRANSFORMATION; CODON; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE RAS; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR GROWTH;

AGOUTI PACA;

EID: 0030710098     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199710)20:2<251::AID-MC12>3.0.CO;2-9     Document Type: Article

References (34)

1. Lu GR, Wu CJ, Ke Y, et al. Inhibited neoplastic phenotype by the c-Ha-ras antisense RNA. Sci China B 34:1485-1491, 1991.
2. Daaka Y, Wickstrom E. Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells. Oncogene Research 5:267-275, 1990.
3. Saison-Behmoaras T, Tocque B, Rey I, Chassignol M, Thuong NT, Helene C. Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J 10:1111-1118, 1991.
4. Kashani-Sabet M, Funato T, Florenes VA, Fodstad O, Scanlon KJ. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 54:900-902, 1994.
5. Monia BP, Johnston JF, Ecker DJ, Zounes MA, Lima WF, Freier SM. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem 267:19954-19962, 1992.
6. Georges RN, Mukhopadhyay T, Zhang Y, Yen N, Roth JA. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res 53:1743-1746, 1993.
7. Kohl NE, Mosser SD, deSolms SJ, et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 25:1934-1937, 1993.
8. James GL, Goldstein JL, Brown MS, et al. Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells. Science 25:1937-1942, 1993.
9. Sepp-Lorenzino L, Ma Z, Kohl NE, et al. A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and independent growth of human tumor cell lines. Cancer Res 55:5302-5309, 1995.
10. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55:5310-5314, 1995.
11. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 326:455-465, 1992.
12. Yamaguchi K, Enjoji M. Carcinoma of the pancreas: A clinicopathologic study of 96 cases with immunohistochemical observations. Jpn J Clin Oncol 19:14-22, 1989.
13. Kelly DM, Benjamin IS. Pancreatic carcinoma. Ann Oncol 6:19-28, 1995.
14. Almoguera C, Shibata D, Forrester K, et al. Human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554, 1988.
15. Grunewald K, Lyons J, Frohlich A, et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 43:1037-1041, 1989.
16. Mariyama M, Kishi K, Nakamura K, Obata H, Nishimura S. Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients. Jpn J Cancer Res 80:622-666, 1989.
17. Motojima K, Urano T, Nagata Y, Shiku H, Tsunoda T, Kanematsu T. Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma. Am J Gastroenterol 86:1784-1788, 1991.
18. Nagata Y, Abe M, Motoshima K, Nakayama E, Shiku H. Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese. Jpn J Cancer Res 81:135-140, 1990.
19. Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 55:3810-3816, 1995.
20. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 58:185-191, 1994.
21. Suwa H, Yoshimura T, Yamaguchi N, et al. K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines. Jpn J Cancer Res 85:1005-1014, 1994.
22. Hohne MW, Halatsch ME, Kahl GF, Weinel RJ. Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res 52:2616-2619, 1992.
23. Simon B, Weinel R, Hohne M, et al. Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma. Gastroenterology 106:1645-1651, 1994.
24. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32, 1994.
25. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 55:1129-1138, 1995.
26. Yamada H, Yoshida T, Sakamoto H, Terada M, Sugimura T. Establishment of a human pancreatic adenocarcinoma cell line (PSN-1) with amplifications of both c-myc and activated c-Ki-ras by a point mutation. Biochem Biophys Res Commun 140:167-173, 1986.
27. Capon DJ, Seeburg PH, McGrath JP, et al. Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 304:507-513, 1983.
28. Mukhopadhyay T, Tainsky M, Cavender AC, Roth JA. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 51:1744-1748, 1991.
29. Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 4:451-460, 1993.
30. Dosaka-Akita H, Akine K, Hiroumi H, Kinoshita I, Kawakami Y, Murakami A. Inhibition of proliferation by L-myc antisense DNA for the translational initiation site in human small cell lung cancer. Cancer Res 55:1559-1564, 1995.
31. Cai DW, Mukhopadhyay T, Liu Y, Fujiwara T, Roth JA. Stable expression of the wild type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther 4:617-624, 1993.
32. Cajot J, Anderson MJ, Lehman TA, Shapiro H, Briggs AA, Stanbridge EJ. Growth suppression mediated by transfection of p53 in Hut292DM human lung cancer cells expressing endogenous wild-type p53 protein. Cancer Res 52:6956-6960, 1992.
33. Asai A, Miyagi Y, Sugiyama A, et al. Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells: Implication of the tumor suppressor genes for gene therapy. J Neurooncol 19:259-268, 1994.
34. Liu T, El-Nagger AK, McDonnell TJ, et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 55:3117-3122, 1995.